Newsfile Corp
15 Jun 2026, 11:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging channel stuffing and undisclosed related party transactions to inflate reported revenue. — Allegations of financial fraud and revenue manipulation are severe red flags that typically lead to significant valuation corrections and loss of investor trust.
-0.80Culper Research alleged that ADMA's 2025 real growth was -3% compared to a reported 20%. — A direct contradiction of growth figures suggests a fundamental mispricing of the company's actual performance.
-0.70Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following concerns over a short-seller report. — Institutional downgrades reduce buying support and signal a shift in professional sentiment toward the stock.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
The lawsuit alleges ADMA Biologics lacked adequate internal controls. — Poor internal controls increase the risk of future operational errors and regulatory penalties.
-0.40Which stocks this story touches
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and misleading statements, leading to significant stock price declines.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
13h ago
